Semaglutide Pen Injector

DRUG15 trials

Sponsors

Yale University, Aga Khan University, State University of New York at Buffalo, University of Erlangen-Nürnberg Medical School, Virginia Commonwealth University

Conditions

AgingAppetite RegulationAtherosclerosisCardiovascular DiseasesChemically-Induced DisordersChronic Obstructive Pulmonary DiseaseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Early Phase 1

Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan.

Aga Khan UniversityDiabetes Mellitus, Type 2, Weight Change, Body

Start: 2022-03-10End: 2022-12-31Target: 300Updated: 2022-08-05

Phase 1

Feasibility of Semaglutide in Advanced Lung Disease

RecruitingNCT05746039

University of PennsylvaniaChronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Obesity +2

Start: 2024-01-29End: 2025-12-28Target: 8Updated: 2025-03-17

Subcutaneous Semaglutide in Systemic Scleroderma

RecruitingNCT06149260

Second Xiangya Hospital of Central South UniversityFibrosis, Scleroderma, Systemic, Semaglutide

Start: 2024-02-29End: 2024-12-31Target: 10Updated: 2024-03-05

Phase 2

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

RecruitingNCT05067621

Yale UniversityImpaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood +1

Start: 2023-07-17End: 2027-01-31Target: 60Updated: 2025-05-21

Semaglutide Use in Elderly Obese Patients

CompletedNCT05302596

State University of New York at BuffaloAging, Obesity

Start: 2022-09-01End: 2024-10-30Updated: 2025-04-17

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

RecruitingNCT05424003

Virginia Commonwealth UniversityNAFLD

Start: 2024-02-22End: 2026-02-28Target: 50Updated: 2025-07-03

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

RecruitingNCT06411210

Yale UniversityDiabetes type1, Obesity

Start: 2024-07-16End: 2028-06-30Target: 54Updated: 2025-05-02

GLP-1R Agonist Treatment for Opioid Use Disorder

RecruitingNCT06548490

Milton S. Hershey Medical CenterChemically-Induced Disorders, Mental Disorder, Narcotic-Related Disorders +4

Start: 2025-01-13End: 2026-11-30Target: 200Updated: 2025-08-14

Tailoring Obesity Treatment Trial

SuspendedNCT06619015

Esbjerg Hospital - University Hospital of Southern DenmarkAppetite Regulation, Obesity, PreDiabetes

Start: 2025-09-30End: 2026-12-31Target: 40Updated: 2025-02-28

Phase 3

Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes

RecruitingNCT05569772

Universitaire Ziekenhuizen KU LeuvenGlucose Intolerance After a Recent History of Gestational Diabetes

Start: 2023-09-14End: 2028-12-31Target: 252Updated: 2025-02-10

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

RecruitingNCT05819138

University of Colorado, DenverDiabetes Mellitus, Type 1

Start: 2023-06-21End: 2027-12-01Target: 60Updated: 2026-03-04

Phase 4

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

CompletedNCT05303857

University of Erlangen-Nürnberg Medical SchoolDiabetes Mellitus, Type 2

Start: 2022-03-03End: 2025-04-17Updated: 2025-06-11

Semaglutide and Vascular Regeneration

Canadian Medical and Surgical Knowledge Translation Research GroupAtherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2 +1

Start: 2023-04-29End: 2024-12-31Target: 100Updated: 2023-07-25

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

RecruitingNCT06852391

McMaster UniversityObesity (Disorder)

Start: 2025-06-18End: 2027-12-31Target: 74Updated: 2026-01-14

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

RecruitingNCT06908694

Hamilton Health Sciences CorporationProstate Cancer

Start: 2025-07-02End: 2026-07-31Target: 20Updated: 2025-07-29

Related Papers

Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.

2025-10-301 citations

From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis

Clinical Liver Disease2023-01-132 citations